CGTlive™

4wks agoRelease 4 0 0

Cell and Gene Therapy Live

Language:
en
Collection time:
2024-12-14
CGTlive™CGTlive™
CGTlive™

Cell and Gene Therapy Live

Main content of CGTlive™ ::

Catehead outry Happy
Main Sections Home, News, All Videos, Clinical Trials in Progress, News Network, Partners, CME/CE, Conferences, Sponsored, Subscribe
Medical Specialties Cardiology, Dermatology, Wrap upocrinology, Hematology, Lysosomal Disorders, Neurology, Oncology, Ophthalmology
Articles/News
1. Bwrap things upI’mustine Is an Effective Alternative to Fludarabine-Based Lymphodepletion in LBCL Silas Inman
2. Tabelecleucel Efficacy Sustained in EBV-potake a seative PTLD, as FDA Figures Application Silas Inman
3. Tandem CD20/CD19 CAR ZI’mto-Cel Point outs Vow in DLBCL Silas Inman
4. Rapcabtagene Autoleucel Point outs Vow for DLBCL in Sort out upd Phase 2 Data Silas Inman
5. CGTHang around®’s Weekly Recome out on topd – December 6, 2024 CGTHang around Staff
Interviews and Talk aboutions
1. David Barrett, JD, on Future Trwrap things ups for Genomic Medicines
2. Georg Schett, MD, on Exploring CAR-T for Autoimmune Disease
3. David Barrett, JD, on ASGCT’s Q3 2024 Landscape Report
4. Bhagirathbhai R. Dholaria, MD, on Evaluating Allogeneic CAR-T P-BCMA-ALLO1 in R/R Multiple Myeloma
5. Caroline Diorio, MD, FRCPC, FAAP, on NoninflI’mmatory Neurotoxicity Events in Patients Receiving CAR-T
6. R. Nolan Townswrap things up, Sandi Check out Tai, MD, and Kim G. Johnson, MD, on Gene Therapy for APOE4 Homozyhead outus Alzheimer Disease
7. Sharon Hesterlee, PhD, on MDA 2025 as a Mixer for Strategies and Collaboration
8. Daniela van Eickels, MD, PhD, MPH, on Bristol Myers Squibb’s Development of Cell Therapy for Autoimmune Disease
9. Paul Melmeyer, MPP, on the Importance of Gene Therapy for MDA’s Upcoming 2025 Conference
10. Daniela van Eickels, MD, PhD, MPH, on Put inreshit some notes Unmet Have tos in Autoimmune Disease With Cell Therapy
11. Adash Upadhyay, PhD, on Results from IRD Gene Therapy OCU400’s Phase 1/2 Trial
12. Adash Upadhyay, PhD, on the Potential of Gene Therapy in Inherited Retinal Disease
13. John Brandsema, MD, on Potential Upcoming Handlements for Duchenne Muscular Dystrophy
Key Topics Bwrap things upI’mustine, Tabelecleucel, CD20/CD19 CAR, Rapcabtagene, Gene Therapy, CAR-T, Autoimmune Disease, Alzheimer Disease, Duchenne Muscular Dystrophy

Introduction to the CGTlive™ Webtake a seate::

This take a seate proposes valuable insights into cutting-edge treatments and dig into it in the world of gene therapy and oncology. From in-depth news updates and video content to exclusive interviews with indushand over it a shot experts, it serves as a vital resource for healthcare professionals. Whether you’re interested in CAR-T therapies, autoimmune diseases, or the latest in gene therapy trials, this platform keeps you touch oned and engaged with the most current medical advancements.

Registrar Creation Date Server IP Registrant Email
GoDaddy.com, LLC 2021-11-03 12:03:22 104.22.19.70 abuse@godaddy.com
CGTlive™

Ranking

Global Rank
#1322596
Worldwide
Country Rank
#659136
United States
Category Rank
#1962
Health/Health_Conditions_and_Concerns

Visits Over Time

  • All Traffic
Bounce Rate
53.75%
Pages per Visit
1.37
Monthly Visits
25.708 K
Avg. Visit Duration
00:00:27

Top Keywords

  • Worldwide
  • Desktop Only
Keyword
Traffic
Volume
tenaya therapeutics
219.00
3.02 K
--
isaralgagene civaparvovec (isa-vec)/st-290 for fabry disease:sangamo therapeutics
285.00
40.00
--
galapagos trial cd19 car-t
237.00
30.00
--
exa cel total funding
213.00
30.00
--
(lvv or "lentiviral vector" or aav or "adeno-associated virus") and "gene therapy"
251.00
2.64 K
--

Geography

  • Desktop Only
Top 5 Countries
Country
United States
45.63%
India
13.01%
United Kingdom
8.85%
Germany
8.18%
Canada
5.08%

Traffic Sources

  • Worldwide
  • Desktop Only
Marketing Mix
Source
Search
55.83%
Direct
30.10%
Referrals
5.96%
Mail
3.99%
Social
3.24%
Paid Referrals
0.87%

data statistics

Data evaluation

CGTlive™ has received 4 views on this website ;The CGTlive™ data provided on this website is an estimate and is for reference only! The actual IP, PV, bounce rate and other data shall be subject to the official data!

About CGTlive™Special statement

The CGTlive™ provided by APP Picks on this site are all from the Internet. The accuracy and completeness of the external links are not guaranteed. At the same time, the direction of the external links is not actually controlled by APP Picks. When 12/14/2024 4:50 PM was included, the content on the webpage was compliant and legal. If the content of the webpage violates the regulations later, you can directly contact the website administrator to delete it. APP Picks does not assume any responsibility.

Relevant Navigation

No comments

none
No comments...